"Chari Considers Choosing Proteasome Inhibitors in Relapsed Multiple Myeloma"
Ajai Chari, MD, associate professor, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai discusses the treatment options available to patients with relapsed multiple myeloma. “Although the SWOG study showed that bortezomib, lenalidomide, and dexamethasone were superior to lenalidomide plus dexamethasone—ie, triplets are better than doublets, which I think is well understood in practice—the question that is being asked now is: Should carfilzomib, the more potent proteasome inhibitor, be used in frontline therapy?” He added, “It is important to note that that was just the PI and dexamethasone. When we add an IMID [immunomodulatory drug], it is not recommended to give a dose higher than 36 mg/m.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases